UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 19, 2008
HELICOS BIOSCIENCES CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware |
| 001-33484 |
| 05-0587367 |
(State or Other Jurisdiction of Incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
One Kendall Square |
| 02139 |
(Address of Principal Executive Offices) |
| (Zip Code) |
(617) 264-1800
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Item 7.01 Regulation FD Disclosure.
Helicos BioSciences Corporation (the “Company”) is providing interim stockholder’s equity and outstanding share information as of November 30, 2008, as set forth below for a resulting book value of $0.33 per share.
Book Value per Share = Stockholders’ Equity / Total Shares Outstanding
$0.33 per share = $6,968,118 / 21,055,096 shares
In accordance with General Instruction B.2 of Form 8-K, the information in this Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. The furnishing of the presentation materials is not intended to constitute a representation that such furnishing is required by Regulation FD or that the presentation materials include material investor information that is not otherwise publicly available.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| HELICOS BIOSCIENCES CORPORATION |
| |||
|
|
|
| |||
|
|
|
| |||
|
| By: | /s/ Stephen P. Hall | |||
Date: December 19, 2008 |
| Name: | Stephen P. Hall |
| ||
|
| Title: | Senior Vice President and | |||
|
|
| Chief Financial Officer | |||
3